What should you know about NEJM glioblastoma?

Glioblastoma, also called GBM, begins in supportive cells of the brain. It can cause headaches, seizures, weakness, changes in speech or vision, difficulty thinking, or altered behaviour, although symptoms depend on the tumour’s location. A brain scan can show a suspicious lesion, but tissue examination is generally needed to establish the diagnosis and its molecular features.

The care team considers how much tumour can be reached safely, the person’s neurological function, overall health, and the laboratory findings. A report or article from a medical journal may provide general information, but it cannot replace an assessment of an individual scan or pathology result.

Ask for a meeting with a neurosurgeon, neuro-oncologist, radiation specialist, and specialist nurse when available. Brain tumour surgery may be used to obtain tissue and remove as much visible tumour as can be done safely. After surgery, radiotherapy and systemic treatment may be discussed to address remaining tumour cells.

Bring your scan reports, pathology wording, medicine list, and a trusted person to appointments if helpful. Ask how treatment may affect fatigue, concentration, seizures, mobility, and daily activities. Clinical trials may be an option for some people; eligibility depends on the diagnosis, previous treatment, health, and the specific study requirements.

Call emergency services for a first seizure, a seizure that does not stop, sudden weakness on one side, loss of consciousness, severe confusion, or sudden difficulty speaking. Contact the medical team promptly for worsening headache with vomiting, increasing drowsiness, new balance problems, or a notable change in vision.

What does my pathology report show, including its molecular features? What is the aim of surgery, radiotherapy, or chemotherapy in my situation? Which symptoms require urgent contact, and are any clinical trials appropriate for me?